Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
Telix Pharmaceuticals today announces the successful preclinical development of radiolabelled olaratumab, an antibody licensed from […]
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
Telix Pharmaceuticals today announces additional positive results from its completed pivotal Phase III ZIRCON study […]
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
Telix Pharmaceuticals today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and […]
Telix Pharmaceuticals ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU Along with Theranostic Pipeline Advances
Telix Pharmaceuticals has announced that the completed pivotal Phase III ZIRCON study of TLX250-CDx in […]
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) […]
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that it has entered into […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more